Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401024 · ClinicalTrials.gov registry record · Phase 1
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00401024 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT00401024, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in the laboratory may help doctors learn how patients respond to treatment. PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving imatinib mesylate for malignant glioma to see how much imatinib mesylate is found in the tumor tissue.
Interventions
- DRUG imatinib mesylate
- OTHER pharmacological study
- PROCEDURE conventional surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-10-12 |
| Est. Completion | 2008-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401024
The ClinicalTrials.gov registry entry for NCT00401024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT00401024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401024 about?
NCT00401024 is a clinical study titled "Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma". RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in the laboratory may help doctors learn how patients respond to treatment. PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving imatinib mesylate for malignant glioma to se...
What is the current status of trial NCT00401024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2006-10-12. Estimated completion is 2008-11-11.
What interventions are being tested in trial NCT00401024?
The interventions under investigation include: imatinib mesylate (DRUG), pharmacological study (OTHER), conventional surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00401024?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.